Multiple Myeloma (MM) is the second most common blood cancer and is considered fatal with a median life expectancy of 3-5 years. Current MM treatment regimes are highly toxic with detrimental side effects. 

Despite recent advances in the treatment of MM, disease relapse remains inevitable.  There is a pressing need for novel safe and efficacious drugs that target any of the complex mechanisms involved in MM pathogenesis. 

Researchers from UTSⁱ have identified a class of small molecules that causes MM cell death via a novel pathway.  These compounds have been tested in vitro and in vivo and have the potential to replace current therapeutics for MM which are highly toxic and have detrimental side effects.

• Sponsored research 
• Licenceⁱ